Literature DB >> 35373095

Less is More: Deprescribing Medications in Older Adults with Kidney Disease: A Review.

Dinushika Mohottige1,2, Harold J Manley3, Rasheeda K Hall1,2.   

Abstract

Due to age and impaired kidney function, older adults with kidney disease are at increased risk of medication-related problems and related hospitalizations. One proa ctive approach to minimize this risk is deprescribing. Deprescribing refers to the systematic process of reducing or stopping a medication. Aside from preventing harm, deprescribing can potentially optimize patients' quality of life by aligning medications with their goals of care. For some patients, deprescribing could involve less aggressive management of their diabetes and/or hypertension. In other instances, deprescribing targets may include potentially inappropriate medications that carry greater risk of harm than benefit in older adults, medications that have questionable efficacy, including medications that have varying efficacy by degree of kidney function, and that increase medication regimen complexity. We include a guide for clinicians to utilize in deprescribing, the List, Evaluate, Shared Decision-Making, Support (LESS) framework. The LESS framework provides key considerations at each step of the deprescribing process that can be tailored for the medications and context of individu al patients. Patient characteristics or clinical events that warrant consideration of deprescribing include limited life expectancy, cognitive impairment, and health status changes, such as dialysis initiation or recent hospitalization. We acknowledge patient-, clinician-, and system-level challenges to the depre scribing process. These include patient hesitancy and challenges to discussing goals of care, clinician time constraints and a lack of evidence-based guidelines, and system-level challenges of interoperable electronic health records and limited incentives for deprescribing. However, novel evidence-based tools designed to facilitate deprescribing and future evidence on effectiveness of deprescribing could help mitigate these barriers. This review provides foundational knowledge on deprescribing as an emerging component of clinical practice and research within nephrology.
Copyright © 2021 by the American Society of Nephrology.

Entities:  

Keywords:  aged; deprescriptions; dialysis; geriatric and palliative nephrology; kidney diseases

Mesh:

Year:  2021        PMID: 35373095      PMCID: PMC8786141          DOI: 10.34067/KID.0001942021

Source DB:  PubMed          Journal:  Kidney360        ISSN: 2641-7650


  107 in total

1.  Deprescribing: what is it and what does the evidence tell us?

Authors:  Wade Thompson; Barbara Farrell
Journal:  Can J Hosp Pharm       Date:  2013-05

2.  Health Outcomes of Deprescribing Interventions Among Older Residents in Nursing Homes: A Systematic Review and Meta-analysis.

Authors:  Chong-Han Kua; Vivienne S L Mak; Shaun Wen Huey Lee
Journal:  J Am Med Dir Assoc       Date:  2018-12-21       Impact factor: 4.669

Review 3.  9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2019.

Authors: 
Journal:  Diabetes Care       Date:  2019-01       Impact factor: 19.112

4.  The effect of hospitalization on potentially inappropriate medication use in older adults with chronic kidney disease.

Authors:  Wubshet H Tesfaye; Barbara C Wimmer; Gregory M Peterson; Ronald L Castelino; Matthew D Jose; Charlotte McKercher; Syed Tabish R Zaidi
Journal:  Curr Med Res Opin       Date:  2019-01-11       Impact factor: 2.580

5.  Does the addition of a pharmacist transition coordinator improve evidence-based medication management and health outcomes in older adults moving from the hospital to a long-term care facility? Results of a randomized, controlled trial.

Authors:  Maria Crotty; Debra Rowett; Lisa Spurling; Lynne C Giles; Paddy A Phillips
Journal:  Am J Geriatr Pharmacother       Date:  2004-12

Review 6.  Blood Pressure Goals in Patients with CKD: A Review of Evidence and Guidelines.

Authors:  Alex R Chang; Meghan Lóser; Rakesh Malhotra; Lawrence J Appel
Journal:  Clin J Am Soc Nephrol       Date:  2018-11-19       Impact factor: 8.237

Review 7.  Tamsulosin versus terazosin for benign prostatic hyperplasia: a systematic review.

Authors:  ZhiLong Dong; ZhiPing Wang; KeHu Yang; YaLi Liu; WenHui Gao; WenYuan Chen
Journal:  Syst Biol Reprod Med       Date:  2009-08       Impact factor: 3.061

8.  Development and validation of the medication regimen complexity index.

Authors:  Johnson George; Yee-Teng Phun; Michael J Bailey; David C M Kong; Kay Stewart
Journal:  Ann Pharmacother       Date:  2004-07-20       Impact factor: 3.154

Review 9.  Patient barriers to and enablers of deprescribing: a systematic review.

Authors:  Emily Reeve; Josephine To; Ivanka Hendrix; Sepehr Shakib; Michael S Roberts; Michael D Wiese
Journal:  Drugs Aging       Date:  2013-10       Impact factor: 3.923

Review 10.  Using Patient-Reported Measures to Improve Outcomes in Kidney Disease.

Authors:  Sofia Mclaren; Manisha Jhamb; Mark Unruh
Journal:  Blood Purif       Date:  2021-04-12       Impact factor: 2.614

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.